OTCPK:ARLZQ - Post by User
Comment by
snootchybootchyon Feb 27, 2016 4:05pm
136 Views
Post# 24602131
RE:Zack's article and initiation report
RE:Zack's article and initiation reportGood report. This is the first time I've heard about the petition to invalidate the Vimovo patent. The author doesn't think this is much of a risk. Is there any risk that if the Vimovo petition is somehow successful, that CFAD will then try to target the Yosprala patent?
Other than the presumption that Yosprala is approved and the Vimovo petition is unsuccessful, I found the revenue assumptions to be fairly conservative. Could be a triple from here in 18 to 24 months if Mr. Adams makes some shrewd moves with the warchest he has.